Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the five ratings firms that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $25.6667.
Several equities research analysts have recently weighed in on UNCY shares. Guggenheim lowered their target price on shares of Unicycive Therapeutics from $46.00 to $40.00 and set a "buy" rating on the stock in a report on Thursday, April 2nd. Benchmark lowered their target price on shares of Unicycive Therapeutics from $21.00 to $15.00 and set a "speculative buy" rating on the stock in a report on Monday. Westpark Capital started coverage on shares of Unicycive Therapeutics in a report on Thursday, February 19th. They issued a "buy" rating on the stock. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Unicycive Therapeutics in a report on Friday, March 27th.
View Our Latest Analysis on UNCY
Institutional Investors Weigh In On Unicycive Therapeutics
Large investors have recently made changes to their positions in the company. Lazard Asset Management LLC bought a new stake in shares of Unicycive Therapeutics in the 2nd quarter worth about $55,000. JPMorgan Chase & Co. grew its holdings in Unicycive Therapeutics by 11,698.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company's stock worth $104,000 after acquiring an additional 21,525 shares during the last quarter. Citadel Advisors LLC bought a new stake in Unicycive Therapeutics during the 3rd quarter worth about $182,000. Quadrature Capital Ltd bought a new stake in Unicycive Therapeutics during the 4th quarter worth about $226,000. Finally, State Street Corp grew its holdings in Unicycive Therapeutics by 19.0% during the 4th quarter. State Street Corp now owns 65,227 shares of the company's stock worth $376,000 after acquiring an additional 10,400 shares during the last quarter. Institutional investors own 40.42% of the company's stock.
Unicycive Therapeutics Stock Performance
Shares of UNCY stock opened at $6.65 on Friday. The firm has a fifty day moving average of $6.64 and a 200-day moving average of $5.88. Unicycive Therapeutics has a 52-week low of $3.71 and a 52-week high of $11.00. The stock has a market cap of $167.83 million, a price-to-earnings ratio of -3.06 and a beta of 1.81.
Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) last posted its earnings results on Monday, March 30th. The company reported ($0.82) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.36). On average, sell-side analysts predict that Unicycive Therapeutics will post -0.23 earnings per share for the current year.
About Unicycive Therapeutics
(
Get Free Report)
Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Unicycive Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Unicycive Therapeutics wasn't on the list.
While Unicycive Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
